Dashboard
Manage Tickers

NBYNovaBay Pharmaceuticals, Inc.

NYSE novabay.com


$ 0.09 $ 0.00 (5.44 %)    

Friday, 03-May-2024 15:25:22 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 0.0949
$ 0.10
$ 0.00 x 0
$ 0.00 x 0
$ 0.09 - $ 0.10
$ 0.07 - $ 1.28
1,480,092
na
2.86M
$ -0.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-26-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-29-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-29-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-21-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-11-2017 03-31-2017 10-Q
29 03-23-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-12-2016 03-31-2016 10-Q
33 03-04-2016 12-31-2015 10-K
34 11-16-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-26-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
39 07-31-2014 06-30-2014 10-Q
40 05-01-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

novabay-pharmaceuticals-notified-by-nyse-american-of-stockholder-equity-compliance-issue
NovaBay Pharmaceuticals Notified By NYSE A...
04/22/2024 07:31:05

novabay-pharmaceuticals-reports-preliminary-q1-fy24-net-revenue-for-its-eyecare-and-wound-care-business-of-26m-up-13-yoy
NovaBay Pharmaceuticals Reports Preliminar...
04/17/2024 11:01:26

novabay-pharmaceuticals-q4-earnings-insights
NovaBay Pharmaceuticals: Q4 Earnings Insights
03/26/2024 21:20:05

novabay-pharmaceuticals-q4-eps-021-beats-030-estimate-sales-373m-beat-340m-estimate
NovaBay Pharmaceuticals Q4 EPS $(0.21) Bea...
03/26/2024 21:18:41

NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-march-26-2024
Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

novabay-reported-preliminary-2023-sales-of-147m-consisting-of-36m-from-its-dermadoctor-skincare-segment-and-111m-from-its-eyecare-and-wound-care-segment-versus-consensus-of-1440m
Novabay Reported Preliminary 2023 Sales Of...
03/14/2024 12:08:09

Operating loss for the 2023 fiscal year is expected to be approximately $7.4 million, which includes a $3.8 million loss in the...

novabay-reported-preliminary-q4-2023-sales-of-37m-consisting-of-09m-from-its-dermadoctor-skincare-segment-and-28m-from-its-eyecare-and-wound-care-segment-versus-consensus-of-34m
Novabay Reported Preliminary Q4 2023 Sales...
03/14/2024 12:06:23

Operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million, due primarily to the $2.7 million l...

novabay-pharmaceuticals-agrees-to-sell-its-dermadoctor-skincare-business-including-all-product-inventory-for-approximately-1m-in-cash
Novabay Pharmaceuticals Agrees To Sell Its...
03/14/2024 12:02:18

Core News & Articles
NovaBay Pharmaceuticals And Eyenovia To Co...
03/13/2024 11:08:19

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/06/2024 13:06:31

novabay-pharmaceuticals-reports-64-yoy-growth-in-avenova-unit-subscription-based-sales-38-increase-in-subscription-based-customers-in-2023-yoy
NovaBay Pharmaceuticals Reports 64% YoY Gr...
01/30/2024 14:30:29

A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022. In addition, of the mor...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
01/29/2024 21:31:25

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
01/29/2024 13:06:03

why-zim-integrated-shipping-services-shares-are-trading-higher-by-9-here-are-20-stocks-moving-premarket
Why ZIM Integrated Shipping Services Share...
01/29/2024 12:56:17

ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares rose sharply in today's pre-market trading after Jefferies upgrade...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
01/26/2024 21:31:13

Core News & Articles
NovaBay Pharmaceuticals And Sonoma Pharmac...
01/09/2024 14:18:12

The new products will combine Sonoma's existing eye product Ocudox®, which has already received a Class IIB CE mark for sal...

novabay-pharmaceuticals-partners-with-woo-university-to-educate-eyecare-professionals-on-the-use-of-amniotic-membranes
NovaBay Pharmaceuticals Partners With Woo ...
12/06/2023 11:59:08

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces its partnership with Woo University to support the education of eyecare prof...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
11/30/2023 21:31:04

recap-novabay-pharmaceuticals-q3-earnings
Recap: NovaBay Pharmaceuticals Q3 Earnings
11/09/2023 21:35:59

novabay-pharmaceuticals-q3-2023-gaap-eps-037-beats-040-estimate-sales-327m-miss-355m-estimate
NovaBay Pharmaceuticals Q3 2023 Gaap EPS $...
11/09/2023 21:30:50

NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION